In the U.S., hospital-acquired infections are responsible for nearly 99,000 deaths annually. These numbers include urinary tract, surgical site, pneumonia, and bloodstream infections.

As part of our efforts to respond to this threat, we collaborate with Venatorx Pharmaceuticals in Pennsylvania to advance a new antibiotic treatment for these infections.

1 in 5 people in the U.S. has a sexually transmitted infection. Among the most common is gonorrhea, with 1.6 million new cases annually. This infection can cause infertility in women and increase the risk of developing HIV/AIDS. The bacteria responsible for gonorrhea has become increasingly resilient to all available antibiotics, leaving only one recommended treatment option. This is why it is listed by the CDC among the most urgent public health threats posed by antibiotic resistance.

Working in partnership with Entasis Therapeutics, a Boston-based company, we are evaluating a new antibiotic to ensure gonorrhea remains treatable for years to come.

We are building a powerful portfolio of antibiotic treatments. Our strategy focuses on three of the five most urgent threats identified by the CDC: carbapenem-resistant Acinetobacter, carbapenem-

resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.

Our portfolio includes antibiotics that are active against Pseudomonas aeruginosa, which the CDC identified as a “serious threat.” We also develop antibiotics for children, a neglected area of drug research.